Olathe-based Innara Health is setting its sights on international expansion, and its acceptance into a national accelerator program could help that goal come to fruition.
Image: Innara Health’s NTrainer System helps infants born prematurely transition to oral feeding. INNARA HEALTH
Across Maryland and the BioHealth Capital Region (BHCR), state-level support for veteran-owned and operated life science businesses is strong.
This is evidenced by the rich and diverse tapestry of veteran led life science organizations in the region that spans a number of disciplines, including genomics, regenerative medicine, lab equipment and support, testing and biorisk management services.
Here are BHCR veteran-owned life science companies to keep an eye on as we move deeper into 2020.
Image: https://biobuzz.io
GAITHERSBURG, Md., July 06, 2020 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced a five-year manufacturing services agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for large-scale drug substance manufacturing for Johnson & Johnson’s investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant based on the AdVac® technology. Emergent will provide contract development and manufacturing (CDMO) services to produce drug substance at large scale over five years, valued at approximately $480 million for the first two years.
At BioBuzz, we’ve been chronicling the BioHealth Capital Region’s contributions to the battle against the coronavirus pandemic. We’ve covered BHCR companies developing vaccine candidates and creating diagnostic and serological COVID-19; we’ve also written about companies across the region that have delivered essential materials for the fight against COVID-19 and pivoted their business models to help the region navigate this public health crises.
Image: https://biobuzz.io
The UMB-born startup was co-founded by cardiac surgery chief Dr. James Gammie, who was previously involved with another company that was acquired in 2017 for up to $250 million.
Inner Harbor-based biotech company PathSensors will be acquired by global security screening and threat detection company Smiths Detection, the companies announced this week.
With the deal, PathSensors will become part of a London-based company with 2,200 employees and a U.S. headquarters in Edgewood.
Image: PathSensors is headquartered at Columbus Center. (Photo by Wikimedia Commons user Smash the Iron Cage, used under Creative Commons license)
Gentian Diagnostics AS is pleased to announce that the Research Council of Norway (Norges Forskningsråd) has awarded Gentian up to NOK 8.0 million of funding to support the development of a high-throughput COVID-19 antibody test. Gentian has in cooperation with Professor Ørjan Olsvik and Dr. Vegard Skogen at the University of Tromsø, The Arctic University of Norway performed explorative test work that supports an idea of developing a COVID-19 antibody test based on Gentian’s proprietary technology. The assay, if successfully developed, will be designed for use on clinical analysers already available in major laboratories around the world.
Welcome to GEN’s COVID-19 DRUG & VACCINE CANDIDATE TRACKER website.
Total Drug & Vaccine Candidates: 237 (as of June 8)
The goal of this resource is to provide a comprehensive collection of news, milestones, and updates on drug and vaccine candidates currently being developed for the COVID-19 pandemic.
This resource is based on the reporting of GEN senior news editor Alex Philippidis, who began compiling information on drug and vaccine candidates in the early weeks of the pandemic. The numbers of verified candidates ballooned rapidly from 35 in February 2020, to 60 in March, to 160 in April.
September 12, 2020
Special Guests Including:
Dr. Michele McMurry-Hearth
President and CEO,
Biotechnology Innovation Organization (BIO)
